journal article·2020-07-23Open access

Computational Drug Repositioning: Current Progress and Challenges

Younhee Ko

Applied Sciences· Volume 10· Issue 15

Abstract

Novel drug discovery is time-consuming, costly, and a high-investment process due to the high attrition rate. Therefore, many trials are conducted to reuse existing drugs to treat pressing conditions and diseases, since their safety profiles and pharmacokinetics are already available. Drug repositioning is a strategy to identify a new indication of existing or already approved drugs, beyond the scope of their original use. Various computational and experimental approaches to incorporate available resources have been suggested for gaining a better understanding of disease mechanisms and the identification of repurposed drug candidates for personalized pharmacotherapy. In this review, we introduce publicly available databases for drug repositioning and summarize the approaches taken for drug repositioning. We also highlight and compare their characteristics and challenges, which should be addressed for the future realization of drug repositioning.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Computational Drug Discovery Methods · Pharmacogenetics and Drug Metabolism · Bioinformatics and Genomic Networks

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Biomedical Engineering, Hankuk University of Foreign Studies, Kyoungki-do 17035, Korea

References (74)

Show source-provided references
1. Diagnosing the decline in pharmaceutical R&D efficiency10.1038/nrd3681 ↗
2. Drug repositioning: Identifying and developing new uses for existing drugs10.1038/nrd1468 ↗
3. Finding hidden treasures in old drugs: The challenges and importance of licensing generics10.1016/j.drudis.2017.08.008 ↗
4. Literature mining, ontologies and information visualization for drug repurposing10.1093/bib/bbr005 ↗
5. Exploiting drug-disease relationships for computational drug repositioning10.1093/bib/bbr013 ↗
6. In silico repositioning of approved drugs for rare and neglected diseases10.1016/j.drudis.2011.02.016 ↗
7. Drug repositioning for orphan diseases10.1093/bib/bbr021 ↗
8. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent10.3332/ecancer.2014.485 ↗
9. New use for old drugs? Prospective targets of chloroquines in cancer therapy10.2174/1389450115666140714121514 ↗
10. DrugBank 5.0: A major update to the DrugBank database for 201810.1093/nar/gkx1037 ↗
11. ChemBank: A small-molecule screening and cheminformatics resource database10.1093/nar/gkm843 ↗
12. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses10.1002/cpbi.5 ↗
13. OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders10.1093/nar/gku1205 ↗
14. PubChem Substance and Compound databases10.1093/nar/gkv951 ↗
15. The ChEMBL database in 201710.1093/nar/gkw1074 ↗
16. DrugCentral: Online drug compendium10.1093/nar/gkw993 ↗
17. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease10.1126/science.1132939 ↗
18. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles10.1016/j.cell.2017.10.049 ↗
19. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations10.1016/j.cels.2017.11.001 ↗
20. Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: Integrated access to diverse large-scale cellular perturbation response data10.1093/nar/gkx1063 ↗
21. The RCSB protein data bank: Integrative view of protein, gene and 3D structural information
22. ProBiS-ligands: A web server for prediction of ligands by examination of protein binding sites10.1093/nar/gku460 ↗
23. PLIP: Fully automated protein-ligand interaction profiler10.1093/nar/gkv315 ↗
24. The Drug Repurposing Hub: A next-generation drug library and information resource10.1038/nm.4306 ↗
25. Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions10.1016/j.chembiol.2017.11.009 ↗
26. Open Targets: A platform for therapeutic target identification and validation10.1093/nar/gkw1055 ↗
27. A standard database for drug repositioning10.1038/sdata.2017.29 ↗
28. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning10.1093/bib/bbw136 ↗
29. STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data10.1093/nar/gkv1277 ↗
30. A comprehensive map of molecular drug targets10.1038/nrd.2016.230 ↗
31. Yella, J.K., Yaddanapudi, S., Wang, Y., and Jegga, A.G. (2018). Changing Trends in Computational Drug Repositioning. Pharmaceuticals, 11.10.20944/preprints201805.0011.v1 ↗
32. A survey of current trends in computational drug repositioning10.1093/bib/bbv020 ↗
33. Drug repurposing: Progress, challenges and recommendations10.1038/nrd.2018.168 ↗
34. Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics10.1080/17460441.2020.1704729 ↗
35. Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping10.1186/1744-8069-6-56 ↗
36. Docking and scoring in virtual screening for drug discovery: Methods and applications10.1038/nrd1549 ↗
37. Predicting new indications for approved drugs using a proteochemometric method10.1021/jm300576q ↗
38. Structures of G protein-coupled receptors reveal new opportunities for drug discovery10.1016/j.drudis.2015.08.003 ↗
39. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds10.3389/fchem.2018.00138 ↗
40. Computational polypharmacology analysis of the heat shock protein 90 interactome10.1021/ci5006959 ↗
41. Predicting new molecular targets for known drugs10.1038/nature08506 ↗
42. Target prediction utilising negative bioactivity data covering large chemical space10.1186/s13321-015-0098-y ↗
43. Exploring activity cliffs in medicinal chemistry10.1021/jm201706b ↗
44. Shape-based reprofiling of FDA-approved drugs for the H(1) histamine receptor10.1021/jm300671m ↗
45. Identification of small molecules enhancing autophagic function from drug network analysis10.4161/auto.6.8.13551 ↗
46. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay10.1126/science.1233606 ↗
47. Adie, E.A., Adams, R.R., Evans, K.L., Porteous, D.J., and Pickard, B.S. (2005). Speeding disease gene discovery by sequence based candidate prioritization. BMC Bioinform., 6.10.1186/1471-2105-6-55 ↗
48. The SIDER database of drugs and side effects10.1093/nar/gkv1075 ↗
49. Drug target identification using side-effect similarity10.1126/science.1158140 ↗
50. Smith, S.B., Dampier, W., Tozeren, A., Brown, J.R., and Magid-Slav, M. (2012). Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS ONE, 7.10.1371/journal.pone.0033174 ↗
51. Iorio, F., Saez-Rodriguez, J., and di Bernardo, D. (2013). Network based elucidation of drug response: From modulators to targets. BMC Syst. Biol., 7.10.1186/1752-0509-7-139 ↗
52. Understanding multicellular function and disease with human tissue-specific networks10.1038/ng.3259 ↗
53. Use of genome-wide association studies for drug repositioning10.1038/nbt.2151 ↗
54. Grover, M.P., Ballouz, S., Mohanasundaram, K.A., George, R.A., Goscinski, A., Crowley, T.M., Sherman, C.D., and Wouters, M.A. (2015). Novel therapeutics for coronary artery disease from genome-wide association study data. BMC Med. Genom., 8.10.1186/1755-8794-8-S2-S1 ↗
55. New human gene tally reignites debate10.1038/d41586-018-05462-w ↗
56. Rational drug repositioning by medical genetics10.1038/nbt.2758 ↗
57. Finan, C., Gaulton, A., Kruger, F.A., Lumbers, R.T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., and Santos, R. (2017). The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med., 9.10.1126/scitranslmed.aag1166 ↗
58. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci10.1038/ng.717 ↗
59. Wu, H., Gao, L., Dong, J., and Yang, X. (2014). Detecting overlapping protein complexes by rough-fuzzy clustering in protein-protein interaction networks. PLoS ONE, 9.10.1371/journal.pone.0091856 ↗
60. Yu, L., Huang, J., Ma, Z., Zhang, J., Zou, Y., and Gao, L. (2015). Inferring drug-disease associations based on known protein complexes. BMC Med. Genom., 8.10.1186/1755-8794-8-S2-S2 ↗
61. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm10.1093/bioinformatics/btw228 ↗
62. Identification of new candidate drugs for lung cancer using chemical-chemical interactions, chemical-protein interactions and a K-means clustering algorithm10.1080/07391102.2015.1060161 ↗
63. Unfolding communities in large complex networks: Combining defensive and offensive label propagation for core extraction10.1103/PhysRevE.83.036103 ↗
64. Emig, D., Ivliev, A., Pustovalova, O., Lancashire, L., Bureeva, S., Nikolsky, Y., and Bessarabova, M. (2013). Drug target prediction and repositioning using an integrated network-based approach. PLoS ONE, 8.10.1371/journal.pone.0060618 ↗
65. Vanunu, O., Magger, O., Ruppin, E., Shlomi, T., and Sharan, R. (2010). Associating genes and protein complexes with disease via network propagation. PLoS Comput. Biol., 6.10.1371/journal.pcbi.1000641 ↗
66. Li, J., Zhu, X., and Chen, J.Y. (2009). Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput. Biol., 5.10.1371/journal.pcbi.1000450 ↗
67. DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data10.1016/j.artmed.2014.11.003 ↗
68. Literature-based prediction of novel drug indications considering relationships between entities10.1039/C7MB00020K ↗
69. A Simple Text Mining Approach for Ranking Pairwise Associations in Biomedical Applications
70. Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., and Rogaeva, E. (2016). Drug Repositioning for Alzheimer’s Disease Based on Systematic ‘omics’ Data Mining. PLoS ONE, 11.10.1371/journal.pone.0168812 ↗
71. Opportunities for drug repositioning from phenome-wide association studies10.1038/nbt.3183 ↗
72. Drug repurposing and the prior art patents of competitors10.1016/j.drudis.2014.09.016 ↗
73. Quantitative and Systems Pharmacology 3. Network-Based Identification of New Targets for Natural Products Enables Potential Uses in Aging-Associated Disorders10.3389/fphar.2017.00747 ↗
74. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia10.3389/fphar.2017.00110 ↗